Cellular processes linked with the initiation of centrosome duplication, mitosis and serine metabolism could be possibly involved in determining the responsiveness of BRAF mutant colon cancer cells to BRAF inhibition by vemurafenib, where nucleophosmin and its interaction partner and downstream target c-Myc play central regulatory roles. Here, NPM1 is linked to malignant colon neoplasm.